0
Abstract: Slide Presentations |

LONG-TERM FOLLOW UP AFTER SUCCESSFUL DISCONTINUATION OF PROSTACYCLIN ANALOGUES IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION (PAH) FREE TO VIEW

Enrique Diaz Guzman Zavala, MD*; Omar Minai, MD; Nancy Bair, RN; Svetlana Banjac, RN; Alejandro Arroliga, MD
Author and Funding Information

Cleveland Clinic Foundation, Cleveland, OH


Chest


Chest. 2005;128(4_MeetingAbstracts):161S. doi:10.1378/chest.128.4_MeetingAbstracts.161S
Text Size: A A A
Published online

Abstract

PURPOSE:  Previous reports have indicated that the addition of bosentan to the treatment regimen of patients with PAH may allow the successful discontinuation of parenteral prostacyclin analogues. There are no reports of long-term outcomes in such patients.

METHODS:  We reviewed the medical records of patients in whom prostacyclin analogues were successfully discontinued after the addition of bosentan. Data collected included demographics, cause of PAH, NYHA class, BNP, echocardiography, and 6 minute walk (6MW).

RESULTS:  With the addition of bosentan, prostacyclin analogues were successfully discontinued in eight patients with PAH, mean age 44 yrs. (range 33-61), 7 females/1 male. Etiology of PAH included iPAH (N=4), SLE-PH (N=3), and HIV-PH (N=1). Six patients were taken off intravenous epoprostenol and 2 were taken off subcutaneous remodulin. Mean duration of follow-up after discontinuation of therapy was 27.5 months (range: 12-33). During the course of follow-up 2 patients required the addition of sildenafil. All patients have continued to do very well clinically at last follow-up in NYHA II (N= 7) or NYHA I (N=1), mean 6MW distance 1329 ft, mean BNP 95 pg/ml (range 5-164), and mean RVSP 63 mmHg (range 34-93).

CONCLUSION:  With the addition of bosentan, intravenous or subcutaneous prostacyclin analogues may be successfully discontinued in selected patients with PAH.

CLINICAL IMPLICATIONS:  In appropriately selected patients, the addition of bosentan helps to the successful discontinuation of prostacyclin analogues without deterioration of the functional capacity over long-term follow up.

DISCLOSURE:  Enrique Diaz Guzman Zavala, None.

Monday, October 31, 2005

2:30 PM - 4:00 PM


Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543